National and Kapodistrian University of Athens
Η αντιμετώπιση των συμπτωμάτων του κατώτερου ουροποιητικού (LUTS) σε ασθενείς με πολλαπλή σκλήρυνση (MS) με την χρήση B3 αγωνιστών ή αντιχολινεργικών
Abstract
dc:descriptionIntroduction and objective: Multiple Sclerosis is the most frequent autoimmune demyelinating disease of the Central Nervous System. Patients usually present with lower urinary tract dysfunction symptoms. Objective of this study is to evaluate and compare the efficacy and safety of treating multiple sclerosis patients with lower urinary tract dysfunction symptoms with either a b3 agonist (mirabegron) or anticholinergics. The study’s primary outcome is the lower urinary tract symptom improvement. Material and Methods: This is a randomized, multi-center, single-blinded, comparative study including 91 multiple sclerosis patients with lower urinary tract dysfunction. At baseline patients underwent thorough clinical examination, urine cultivation and abdominal ultrasound and completed urination diaries and specific, validated questionnaires (NBSS, MusiQoL). At second visit patients were administered either mirabegron or anticholinergics. Treatment was always carried out alongside with multiple sclerosis treatment. Reevaluation was performed 3 months after first visit. Patients underwent the same clinical and imaging tests that were carried out at first visit. Results: We compared several clinical and imaging parameters between the two groups at first visit and month 3 after treatment. Νo statistical difference was noted between the mirabegron group and the anticholinergic group in terms of lower urinary tract symptom improvement. On the other hand, in both groups, improvement from baseline regarding lower urinary tract symptoms was recorded. Statistical analysis was performed using the paired and unpaired t-test method. Side effects were recorded in both groups. No patient discontinued either medication due to side-effects. Conclusions: Multiple sclerosis patients receiving either mirabegron or anticholinergic therapy for lower urinary tract symptoms showed improvement in most of the tested parameters. Nevertheless, no statistical difference was noted between the two cohorts at 3 months in terms of drug efficacy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Glykas, Ioannis
- Γλύκας, Ιωάννης
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51221